dren and the French GOELAL 01 or GOELAL 02 protocols
After achieving hematological CR, nine patients initially received consolidation chemotherapy (CT) according to the EORTC and GOELAL trials. Six received allogeneic BMT in Introduction first or second CR, with an HLA-identical familial donor in two cases, a haplo-identical familial donor in one case and The Ph1 chromosome t(9;22) translocation, found in about an HLA-identical unrelated donor in three cases. The con-20% of adult ALL, and 1% of childhood ALL, results in a ditioning regimen was with cyclophosphamide-total body fusion between the second exon of c-abl gene and generally irradiation (TBI) in all cases. The remaining four patients the first intron of BCR gene (m-bcr breakpoint, e1a2 fusion) received autologous BMT in first CR with purged bone maror rarely its second or third exon (M-bcr breakpoint, b3a2 or row in two cases (with mafosfamide in patient 14 and with b2a2 fusion).
1-3 Reverse transcription PCR (RT-PCR) analysis MoAb in patient 15), and unpurged bone marrow in the of these fusion transcripts has demonstrated its usefulness in remaining two patients. For the purpose of this study, patients the diagnosis of Ph1 ALL, especially in cases of cytogenetic were categorized as in Table 1 according to the type of confailure. 4, 5 RT-PCR analysis of BCR-ABL fusion transcripts is solidation treatment after which cytogenetic and molecular also a useful tool in the evaluation of minimal residual disease follow-up was available. Patients 1 to 9 had cytogenetic and (MRD) after treatment (particularly allogeneic BMT) in Ph1-molecular follow-up after consolidation chemotherapy; positive chronic myeloid leukemia. [6] [7] [8] [9] [10] However, very few patients 9 to 13 were studied after allogeneic BMT in second studies have attempted to correlate RT-PCR of these transcripts CR, (patients 9 and 10) and in first CR (patients 11 to 13); and clinical outcome in Ph1-positive ALL. 11, 12 We performed such a study in 17 patients in whom sequential cytogenetic analysis was also made.
Figure 1
Cytogenetic and molecular data of the 17 patients, divided according to the type of consolidation treatment (consolidation chemotherapy, allogeneic BMT, autologous BMT) after which cytogenetic and molecular follow-up was available. Patients 1 to 9 were followed-up after consolidation chemotherapy, patients 9 to 13 after allogeneic BMT and patients 14 to 17 after autologous BMT. With Correspondence: Dr C Preudhomme, Laboratoire d'Hé matologie A, Hô pital Calmette, Boulevard du Professeur Leclercq, 59037 Lille, regard to time of follow-up, 0 means date of CR achievement. For allogeneic BMT, the absence of indications in parentheses means that France Received 24 July 1996; accepted 11 November 1996 the donor was a familial HLA identical donor.
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including two from GVH disease after allogeneic BMT (patients 8 and 11) and one from infection after consolidation CT (patient 2)). Two patients (patients 14 and 15) were alive in first CR after 137 and 20 months, and two patients (patients 7 and 10) were alive in second CR after 26 and 14 months. Of the nine patients followed up after consolidation CT (patients 1 to 9; Table 1), seven relapsed after 5 to 28 months, and two died in CR after 6 and 20 months. Of the five patients followed up after allogeneic BMT (patients 9 to 13), one died from GVH disease (patient 11), three relapsed (patients 9, 12 and 13) and one remained in CR after 17 months (patient 10). Of the four autografted patients (patients 14 to 17), two relapsed after 9 and 13 months, and the two patients who had been autografted with purged marrow were still in first CR after 20 and 137 months.
Cytogenetic results
A total of 54 examinations were performed during follow up. (Figure 1 ). Upon hematological CR achievement, normalization of cytogenetics was observed in 14 cases. PH1 mitoses were still found in one patient and no cytogenetic analysis was performed at this stage in three patients. In eight of the patients who had a hematological relapse, cytogenetics had been performed within 4 months of relapse and no PH1 mitose was found in any case. The four patients who were still in CR (patients 7, 10, 14 and 15), had normal karyotype. Table 1 Sequence and localization of primers RT-PCR results patient 9, followed-up in first CR after chemotherapy and in second CR after allogeneic BMT, therefore appears in both categories in Table 1 ; patients 14 to 17 were autografted; During follow-up, 81 points of RT-PCR analysis were made (Figure 1 ). patient 8, although he was allografted late in first CR, was only categorized in the consolidation chemotherapy group in Of the nine patients followed molecularly after consolidation CT, four patients always remained PCR-positive after Table 1 as no follow-up post-transplant was available.
one round (patients 3, 4, 5) and two rounds (patient 6) in the bone marrow. The three former relapsed after 7, 8 and 5 months, respectively, and the latter after 16 months. Five Methods patients (patients 1, 2, 7, 8 and 9) became two-round PCR negative in the marrow, after 4 to 16 months, patients 2 and Cytogenetic analysis was performed on bone marrow cells, after 24 h in vitro culture without stimulation. Chromosomes 8 died in first CR; patient 1 and 9 relapsed after 22 and 28 months, 4 and 6 months after switch to positivity of two-round were identified by RHG and GTG banding. Thirty to 50 mitoses were analyzed before reaching a conclusion on the PCR, respectively, and patient 7 relapsed after 24 months in the CNS, but not in the bone marrow. In patient 7, PCR had absence of Ph1 chromosome.
PCR analysis was performed on RNA obtained from bone become positive after two rounds in the bone marrow 5 months earlier; 26 months after retreatment with intensive marrow and/or circulating mononuclear leukocytes, as previously published. 1, 6 Briefly, after reverse transcription of chemotherapy, this patient remained in second CR, with negative PCR. RNA, two-step PCR was performed using nested primers, as shown in Table 1 . Positive control cell lines were K562 (MOf the five patients followed molecularly after allogeneic BMT, two (patients 10 and 11) became PCR-negative in the bcr) and TOM1 (m-bcr) a generous gift of A Hagemeijer (Erasmus University, Rotterdam, The Netherlands). In our marrow: patient 11 died from GVH disease after 5 months, and patient 10 remained in CR after 9 months. Patients 9, 12 hands, this PCR technique allows detection of one abnormal K562 or TOM1 cell in 10 4 CEM cells after one round, and 1 and 13 remained one-round PCR-positive in the marrow; they relapsed 6, 10 and 5 months after the procedure, respectively. in 10 6 after two rounds. Precautions taken to minimize contamination problems were as previously published. 6 Of the two patients autografted with a purged marrow patient 15, who had positive two-round PCR in the marrow before the procedure, remained so during 6 months after which PCR became negative in the marrow. She remained in Results CR 12 months later. The other patient (patient 14) was only tested 26 to 116 months after the procedure, while still in CR, Clinical outcome and was always found negative in the marrow. The two patients (patients 16, 17) autografted with unpurged marrow Overall, 12 patients had relapsed. One of the relapses only involved the CNS (patient 7). Three patients died in first CR, were PCR positive before the transplant, remained so after one round, in the marrow after the transplant, and relapsed 2 and whereas both patients who received unpurged BMT relapsed after remaining one-step PCR-positive post-transplant. Miya-9 months after BMT.
Overall, five of nine, two of five and two of four of the mura et al 12 also reported that in five patients autografted with purged marrow, three of the four patients studied by PCR were patients followed molecularly after consolidation CT, alloBMT and autoBMT respectively became negative after two-step positive at the time of bone marrow harvest. They became PCR-negative after transplant and two were in prolonged CR. PCR in the marrow. Three died in CR, three remained in CR with persistently negative two step PCR in the marrow, and
In contrast, the only patient transplanted without marrow purging never became PCR-negative and rapidly relapsed. three relapsed after 22 to 28 months. In all cases, relapse was preceded by switch to PCR positivity in the bone marrow after These findings suggest that bone marrow purging prior to ABMT may be important in Ph1-positive ALL. two-step PCR, by 4 to 6 months. In contrast, the nine patients who remained PCR-positive in the bone marrow had short CR;
Finally, our results also show the lower sensitivity of RT-PCR performed in blood, as compared to bone marrow, in eight patients positive after one round relapsed after 5 to 10 months and one patient positive after two rounds relapsed one third of the samples. Van Rhee et al, 14 using quantitative PCR comparatively in 29 paired specimens of blood and marafter 16 months.
In 35 samples studied concomitantly, a lower sensitivity of row of 18 Ph1-ALL patients collected contemporaneously found similar numbers of BCR-ABL transcripts in 25 samples, RT-PCR performed on blood samples, as compared to bone marrow, was seen in 12 cases (34%). In these samples, PCR but in the remaining four samples, BCR-ABL transcripts were present in BM and absent in PB. was negative in the blood after two rounds but positive in bone marrow after two rounds or positive in the blood after only two rounds, but in the marrow after the first round.
